(190 days)
No
The summary describes a mapping system that acquires and displays data, but there is no mention of AI or ML being used for analysis, interpretation, or decision-making. The description focuses on location technology and data visualization.
No
Explanation: The device is described as a mapping system that provides information about the heart's electrical activity and catheter location during procedures. It does not exert a direct therapeutic effect on the patient.
Yes
The device provides information about the electrical activity of the heart and catheter location, and creates 3D anatomical and electroanatomical maps of the human heart, all of which are used to analyze and interpret the heart's condition, fitting the definition of a diagnostic device.
No
The device description explicitly states that the system acquires location information using "specialized mapping catheters and reference devices" and utilizes "magnetic sensor technology and Advanced Catheter Location (ACL) technology." These are hardware components, indicating it is not a software-only device.
Based on the provided information, the CARTO® 3 System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for "catheter-based cardiac electrophysiological (EP) procedures." This describes a procedure performed on the patient, not a test performed on a sample taken from the patient.
- Device Description: The system acquires and analyzes data points from within the human heart in real-time during a procedure. It uses specialized catheters and reference devices to gather electrical activity and location information directly from the patient's heart.
- Lack of Sample Analysis: IVD devices are designed to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or screening. The CARTO 3 System does not analyze such samples. It directly interacts with and gathers data from the patient's heart during a procedure.
While the system provides information about the electrical activity of the heart, this information is gathered in vivo (within the living body) during a procedure, not in vitro (in glass or outside the living body) by analyzing a sample.
N/A
Intended Use / Indications for Use
The intended use of the CARTO® 3 System is catheter-based cardiac electrophysiological (EP) procedures. The CARTO® 3-System provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional! electrophysiological procedure. The system has no special contraindications.
Product codes
DQK
Device Description
The CARTO 3 System V4.2 is a catheter-based atrial and ventricular mapping system designed to acquire and analyze data points, and use this information to display 3D anatomical and electroanatomical maps of the human heart in real-time. The location information needed to create the cardiac maps and the local electrograms are acquired using a specialized mapping catheters and reference devices. The system allows realtime display of electrograms and cardiac maps based on the received intracardiac signals from the catheters in a number of different formats. The acquired patient, signals, including body surface ECG and intracardiac electrograms (IECG) may also be displayed on the display screen. The CARTO 3 System V4.2 uses two distinct types of location technology-magnetic sensor technology and Advanced Catheter Location (ACL) technology.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
human heart
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The CARTO® 3 EP Navigation System, Version 4.2 underwent extensive Bench and Animal Testing to verify the new and modified features and to demonstrate with regression testing that the new/modified features did not negatively affect existing. features. The CARTO 3 EP Navigation System, Version 4.2 passed all tests in accordance with appropriate test criteria and standards, and the modified device did not raise new questions of safety or effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1425 Programmable diagnostic computer.
(a)
Identification. A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.(b)
Classification. Class II (performance standards).
0
K133916
JUL 0 1 2014
510(K) SUMMARY 14
and the comments of the commend of the bearing the form and the
| 14.1 General Information | |
|---|---|
| Applicant: | Biosense Webster, Inc. |
| 3333 Diamond Canyon Road | |
| Diamond Bar, California 91765 USA | |
| Phone: 909-839-8597 | |
| Fax: 909-839-8804 | |
| Date: | December 19, 2013 |
| Contact Person: | Wayne R. Hohman |
| Project Manager Regulatory Affairs | |
| Authored By: | Moshe Hochmitz |
| Quality and Regulatory Manager | |
| Biosense Webster (ISRAEL), Ltd. | |
| Trade/Proprietary Device Name: | CARTO® 3 EP Navigation System, Version 4.2 and |
| Accessories | |
| Manufacturing Part Number: | FG-5400-00 |
| Common Device Name: | Cardiac mapping system |
| Classification Name: | Programmable diagnostic computer |
| Class II, 21 CFR 870.1425, Product Code DQK | |
| Predicate Devices: | CARTO® 3 EP Navigation System, Version 3.0, cleared |
| via 510(k) K120550, May 7, 2012. | |
| Referenced Device 1 | |
| Siemens MAGNETOM Skyra with Syngo MR D11, | |
| 510(k) K111242 cleared November 23, 2011. | |
| Reference Device 2 | |
| ST JUDE EnSite NavXTM CONTACT, 510(k) | |
| K130727 cleared August 29, 2013, included only for | |
| the VeriSense System Software. | |
| Manufacturing Facilities: | Biosense Webster (Israel), Ltd. |
| a Johnson & Johnson Company | |
| 4 Hatnufa Street, POB 275 | |
| Yokneam 20692 ISRAEL |
Biosense Webster, Inc. CARTO® 3.V4.2 EP Navigation
Traditional 510(k)
Page 104 of 1491
1
K133916
Biosense Webster, Inc. a Johnson & Johnson Company 3333 Diamond Canyon Road Diamond Bar; California 91765 USA
14.2 Substantial Equivalence
The CARTO 3 EP Navigation System, Version 4:2 in substantially equivalent;to the legally marketed CARTO 3 EP Navigation System, Version 3.0 and two Reference Devices as shown in the following Table:
| Predicate Devices for CARTO® 3 EP Navigation System, Version 4.2 | ||
|---|---|---|
| Predicate/Reference Name | 510(k) | |
| Number | Equivalence Criteria | |
| CARTO® 3 EP Navigation | ||
| System, Version 3.0 | K120550 | Main predicate for legacy |
| functionality | ||
| Siemens MAGNETOM | ||
| Skyra with Syngo MR D11 | K111242 | For segmentation functionality |
| ST JUDE EnSite NavXTM | ||
| CONTACT, 510(k) cleared | ||
| August 29, 2013, included | K130727 | For segmentation functionality |
143 Description of Device
The CARTO 3 System V4.2 is a catheter-based atrial and ventricular mapping system designed to acquire and analyze data points, and use this information to display 3D anatomical and electroanatomical maps of the human heart in real-time. The location information needed to create the cardiac maps and the local electrograms are acquired using a specialized mapping catheters and reference devices. The system allows realtime display of electrograms and cardiac maps based on the received intracardiac signals from the catheters in a number of different formats. The acquired patient, signals, including body surface ECG and intracardiac electrograms (IECG) may also be displayed on the display screen. The CARTO 3 System V4.2 uses two distinct types of location technology-magnetic sensor technology and Advanced Catheter Location (ACL) technology.
14.4 Indications for Use
The intended use of the CARTO® 3 System is catheter-based cardiac electrophysiological (EP) procedures. The CARTO® 3-System provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional! electrophysiological procedure. The system has no special contraindications.
Biosense Wabstar, Inc. CARTO® 3 V4.2 EP Navigatio
Traditional 510(k)
Page 105 of 1491
2
14.5 Technological Characteristics
The Proposed CARTO® 3 EP Navigation System, Version 4.2, has the same technological characteristics (i. e., design, material, chemical composition, energy isource) as the predicate CARTO® 3 EP Navigation System, Version 3.0. A summary of the technological characteristics of the new device compared to the predicate device is as follows:
- · The hardware platform of the new Version 4.2 is identical to the predicate Version 3:0 except for replacement of a Printed Circuit Board.
- · The differences between CARTO® 3 System, Version 3.0 and Version 4.2 a mainly three added software features, one of which required a hardware change, as follows:
- CARTOMERGE Plus Image Integration Software Module Improvement.
- Continuous ECG Visualization Module.
- · Tissue Proximity Indication (TPI) Module:
- · Software Feature: Added Tissue Proximity Indication (TPI) algorithms.
- · Hardware Feature: Modified ACL Tx card to add electrode voltage measurement.
- O SMARTTOUCHTM Module.
- In addition, Biosense Webster improved (i. e., enhanced) the capabilities of four previously cleared software features as follows:
- Enhanced VisiTag II Module.
- Enhanced Continuous Acquisition of Electroanatomical Points.
- Enhanced Time-Sync Heart Rhythm for CARTOUNIVUTM Fluoro Background Cine Movies.
- o Enhanced Map Alignment Tool (MAT)
- Finally, Biosense Webster updated FDA on features that were incorporated via 510(k) Letters to File since the last submission: Two new Map Displays New Signal Annotation Options, an additional Foot Pedal (ergonomic feature), support of New Catheters, and support of Dual Monitors.
14.6 Summary of Non-Clinical Performance Testing
The CARTO® 3 EP Navigation System, Version 4.2 underwent extensive Bench and Animal Testing to verify the new and modified features and to demonstrate with regression testing that the new/modified features did not negatively affect existing. features. The CARTO 3 EP Navigation System, Version 4.2 passed all tests in accordance with appropriate test criteria and standards, and the modified device did not raise new questions of safety or effectiveness.
Biosense Webstar, Inc CARTO® 3 V4 2 EP Navi
Traditional 510(k)
Page 106 of 1491
3
14.7 Conclusions
The Bench and Animal Non-Clinical Testing demonstrated that the CARTO® 3.EP
Navigation System, Version 4.2 is as safe, as effective, and performs as well as or better than the predicate device and two reference devices. This testing program
supports the determination of substantial equivalence to the predicate/reference devices.
Biosense Webster, Inc. CARTO® 3 V4.2 EP Navigation
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the seal is the department's symbol, which features a stylized human figure embracing a globe.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
July 1, 2014
Biosense Webster, Inc Wayne R. Hohman Product Manager Regulatory Affairs 3333 Diamond Canyon Road Diamond Bar, CA 91765
- Re: K133916
Trade/Device Name: CARTO 3 EP Navigation System, Version 4.2 Regulation Number: 21 CFR 870.1425 Regulation Name: Programmable Diagnostic Computer Regulatory Class: Class II Product Code: DQK Dated: May 29, 2014 Received: June 2, 2014
Dear Mr. Hohman,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
5
Page 2 - Mr. Wayne R. Hohman
the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the clectronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Image /page/5/Picture/7 description: The image shows the closing of a letter with the phrase "Sincerely yours,". Below the phrase is a signature that is illegible. The signature is written over a logo that is also illegible. The logo appears to be a seal or emblem of some kind.
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
5 INDICATIONS FOR USE
Section of the states
510(k) No (if known):
Device Name: CARTO® 3 EP Navigation System, Version 4.2
Indications for Use:
The intended use of the CARTO® 3 System is catheter-based cardiac electrophysiological (EP) procedures. The CARTO® 3 System provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional electrophysiological procedure. The system has no special contraindications.
Prescription Use _ V (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Date:
2007.01
08.45.22 -04'00'
Blosense Webster, Inc. CARTO® 3 V4.2 EP Navigation
Traditional 510(k) Page 61 of 1491